Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
ALK inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:brand |
gptkb:Alecensa
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
combination therapy
monotherapy NC T01801111 NC T02075840 NC T02259523 |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to alectinib concurrent use of strong CY P3 A4 inducers |
| gptkbp:developed_by |
gptkb:Roche
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
as prescribed by oncologist
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alecensa
|
| gptkbp:indication |
ALK-positive non-small cell lung cancer
|
| gptkbp:ingredients |
gptkb:alectinib
C22 H24 Cl N5 O2 S |
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:invention |
2027
|
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_monitored_by |
cardiac function
liver function tests pulmonary function |
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:label |
FDA approved labeling
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:marketed_as |
gptkb:Alecensa
|
| gptkbp:pharmacokinetics |
high oral bioavailability
inhibits ALK fusion proteins |
| gptkbp:population |
adults
pediatric patients provided with prescription |
| gptkbp:provides_information_on |
included in ESMO guidelines
included in NCCN guidelines |
| gptkbp:safety_features |
risk of lung inflammation
risk of severe allergic reactions risk of bradycardia risk of liver damage |
| gptkbp:side_effect |
fatigue
nausea diarrhea liver enzyme elevation |
| gptkbp:status |
approved for clinical use
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:type_of |
1195760-96-4
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
gptkb:Hoffmann-La_Roche |
| gptkbp:bfsLayer |
5
|